John G.  Houston net worth and biography

John Houston Biography and Net Worth

CEO of Arvinas

Dr. Houston is President and Chief Executive Officer of Arvinas. Previously, he was the SVP of Specialty Discovery at Bristol-Myers Squibb (BMS). He spent more than 18 years at BMS in roles of increasing responsibility and had accountability for all Discovery Biology disease teams as well as various Discovery technology departments. He was also the site head of the BMS Connecticut facility. Dr. Houston was a member of the BMS R&D Executive Leadership team and chaired the Target Portfolio Committee which had governance oversight in the discovery space. With his teams and research colleagues, he progressed over 200 compounds into early development, several of which advanced into late stage clinical trials, and toward commercialization.

He was also the principal architect and driver of the ‘Leveraging Technology’ initiative at BMS which oversaw the design and implementation of an industry-leading integrated lead discovery and optimization process. This initiative created revolutionary changes in the discovery process at BMS with significant improvements in capacity, speed and cost control resulting in marked increases in research productivity and success rates.

Dr. Houston has over 28 years of experience in the pharmaceutical industry. Prior to joining Bristol-Myers Squibb, he worked at Glaxo Welcome Research and Development in the UK, where he served as head of the Lead Discovery Unit. Dr. Houston currently serves on the boards of directors of NextCure, Inc., Oerth Bio, Cybrexa Therapeutics and BioCT.

Dr. Houston obtained his B.Sc. degree in Medical Microbiology from Glasgow University and obtained his Ph.D. with Professor Brian Catley in Microbial Biochemistry from Heriot-Watt University, Edinburgh. He also completed his post-doctoral studies on an MRC grant with Professor Julia Douglas at Glasgow University.

What is John G. Houston's net worth?

The estimated net worth of John G. Houston is at least $9.30 million as of February 24th, 2025. Dr. Houston owns 1,157,480 shares of Arvinas stock worth more than $9,300,352 as of March 26th. This net worth estimate does not reflect any other investments that Dr. Houston may own. Additionally, Dr. Houston receives a salary of $1,140,000.00 as CEO at Arvinas. Learn More about John G. Houston's net worth.

How old is John G. Houston?

Dr. Houston is currently 64 years old. There are 8 older executives and no younger executives at Arvinas. Learn More on John G. Houston's age.

What is John G. Houston's salary?

As the CEO of Arvinas, Inc., Dr. Houston earns $1,140,000.00 per year. Learn More on John G. Houston's salary.

How do I contact John G. Houston?

The corporate mailing address for Dr. Houston and other Arvinas executives is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. Arvinas can also be reached via phone at (203) 535-1456 and via email at ir@arvinas.com. Learn More on John G. Houston's contact information.

Has John G. Houston been buying or selling shares of Arvinas?

Over the course of the past ninety days, John G. Houston has sold $523,971.36 of Arvinas stock. Most recently, John G. Houston sold 31,338 shares of the business's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.72, for a transaction totalling $523,971.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,480 shares of the company's stock, valued at $19,353,065.60. Learn More on John G. Houston's trading history.

Who are Arvinas' active insiders?

Arvinas' insider roster includes Sean Cassidy (CFO), John Houston (CEO), Bradley Margus (Director), Briggs Morrison (Director), Ronald Peck (Insider), Liam Ratcliffe (Director), Timothy Shannon (Director), and Ian Taylor (Insider). Learn More on Arvinas' active insiders.

Are insiders buying or selling shares of Arvinas?

In the last year, insiders at the sold shares 4 times. They sold a total of 50,230 shares worth more than $769,402.28. The most recent insider tranaction occured on March, 18th when insider Noah Berkowitz sold 8,658 shares worth more than $74,372.22. Insiders at Arvinas own 5.2% of the company. Learn More about insider trades at Arvinas.

Information on this page was last updated on 3/18/2025.

John G. Houston Insider Trading History at Arvinas

See Full Table

John G. Houston Buying and Selling Activity at Arvinas

This chart shows John G Houston's buying and selling at Arvinas by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$524ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$400k-$200k$0$200k$400kTotal Insider BuyingTotal Insider Selling

Arvinas Company Overview

Arvinas logo
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Read More

Today's Range

Now: $7.95
Low: $7.93
High: $8.23

50 Day Range

MA: $15.67
Low: $7.95
High: $19.59

2 Week Range

Now: $7.95
Low: $7.91
High: $41.98

Volume

2,037,048 shs

Average Volume

959,813 shs

Market Capitalization

$546.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.95